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Background: Homeostatic turnover of the extracellular matrix
conditions the structure and function of the healthy lung. In
lung transplantation, long-term management remains limited
by chronic lung allograft dysfunction, an umbrella term used
for a heterogeneous entity ultimately associated with
pathological airway and/or parenchyma remodeling.
Objective: This study assessed whether the local cross-talk
between the pulmonary microbiota and host cells is a key
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determinant in the control of lower airway remodeling
posttransplantation.
Methods: Microbiota DNA and host total RNA were isolated
from 189 bronchoalveolar lavages obtained from 116 patients
post lung transplantation. Expression of a set of 11 genes
encoding either matrix components or factors involved in
matrix synthesis or degradation (anabolic and catabolic
remodeling, respectively) was quantified by real-time
quantitative PCR. Microbiota composition was characterized
using 16S ribosomal RNA gene sequencing and culture.
Results: We identified 4 host gene expression profiles, among
which catabolic remodeling, associated with high expression of
metallopeptidase-7, -9, and -12, diverged from anabolic
remodeling linked to maximal thrombospondin and platelet-
derived growth factor D expression. While catabolic remodeling
aligned with a microbiota dominated by proinflammatory
bacteria (eg, Staphylococcus, Pseudomonas, and
Corynebacterium), anabolic remodeling was linked to typical
members of the healthy steady state (eg, Prevotella,
Streptococcus, and Veillonella). Mechanistic assays provided
direct evidence that these bacteria can impact host
macrophage-fibroblast activation and matrix deposition.
Conclusions: Host-microbes interplay potentially determines
remodeling activities in the transplanted lung, highlighting new
therapeutic opportunities to ultimately improve long-term
lung transplant outcome. (J Allergy Clin Immunol
2018;141:718-29.)
Key words: Airway remodeling, fibroblasts, macrophages, matrix,
microbiota
Despite a marked improvement over the last 2 decades, lung
transplantation remains associated with a lower survival rate
(54% at 5 years posttransplantation in 2013),1 compared with the
rates for heart, kidney, liver, and pancreas transplantations. In
fact, long-term management of the lung allograft faces a major,
as yet incompletely characterized condition: chronic lung
allograft dysfunction (CLAD), an umbrella term used to describe
different phenotypes of chronic lung allograft rejection, for
which a general consensus on the precise clinical definition is
still lacking. The heterogeneity of CLAD phenotypes
reflects the complexity of the underlying mechanisms, whereby
inflammation combined with aberrant airway and/or parenchyma
remodeling progressively impairs lung function, ultimately
leading to retransplantation or death.2 Consequently, there is an
urgent need for increasing our understanding of CLAD
pathophysiology and identifying biomarkers that are specific for
the different CLAD phenotypes.
A rich and balanced airwaymicrobiota has been linkedwith the
maintenance of local tissue homeostasis. Perturbation in the
composition of this microbial community, known as dysbiosis,
has been reported in a variety of respiratory conditions, including
lung transplantation.3-6 We recently showed that there is a
predominance of proinflammatory (eg, Staphylococcus and Pseu-
domonas) or low stimulatory (eg, Prevotella and Streptococcus)
bacteria aligned with inflammatory or tissue remodeling gene
expression profiles, respectively, in bronchoalveolar lavage
(BAL) cells following transplantation, which suggests that the
pulmonary microbiota may impact long-term graft survival.7
In the present study, we sought to dissect host-microbe
interactions in the context of the complex remodeling processes
taking place following lung transplantation. We show that the
transplanted lung presents distinct remodeling profiles,
characterized by the expression of genes differentially involved
in matrix synthesis or degradation. In addition, we provide
evidence that the constituents of microbial communities
dominated by these bacterial taxa fine-tune gene expression
profiles in macrophages and fibroblasts—2 key cell types in the
regulation of remodeling processes.
METHODS
Patient sample collection and ethics statement
BAL samples were collected during surveillance bronchoscopies carried
out during the first 14 months posttransplantation, from October 2012 to July
2014 in 6 Swiss and French transplantation centers, within the framework of
the European project System prediction of Chronic Lung Allograft
Dysfunction (SysCLAD).8 The national and local ethics committees approved
the study, and all subjects, whose details are provided in Table I,9 gave written
informed consent.
Detail on BAL fluid collection and processing is provided in theMethods in
this article’s Online Repository (available at www.jacionline.org). BAL fluid
was submitted to cell differential determination, culture-dependent bacterial
and fungal detection, and PCR-based detection of viral infection, according
to routine clinical procedures. Negative control samples obtained on washing
a ready-to-use endoscopewith sterile saline were prepared following the same
procedure.
RNA-seq and data analysis
Total BAL cellular RNA converted into cDNA libraries using the Illumina
TruSeq RNA Sample Preparation Kit (Illumina, San Diego, Calif) was
submitted to high throughput sequencing using the Illumina HiSeq 2500
System. Gene expression quantification was based on reads per kilobase of
exon model per million mapped reads.
Extraction of remodeling genes from Gene
Ontology database
A panel of 627 remodeling-related genes were extracted from Gene
Ontology (GO) database (release May 2016) using the browser AmiGo10
(version 2.3), based on GO Terms listed in Fig 1, B.
Abbreviations used
BAL: Bronchoalveolar lavage
CFU: Colony-forming unit
CHI3L1: Chitinase 3-like 1
CLAD: Chronic lung allograft dysfunction
COPD: Chronic obstructive pulmonary disease
GO: Gene Ontology
IGF: Insulin-like growth factor
IQR: Interquartile range
KEGG: Kyoto Encyclopedia of Genes and Genomes
KO: KEGG ortholog
MMP: Matrix metallopeptidase
PDGFD: Platelet-derived growth factor D
rRNA: Ribosomal RNA
SPP1: Secreted phosphoprotein 1
SysCLAD: System prediction of Chronic Lung Allograft Dysfunction
THBS1: Thrombospondin 1
THP-DM: THP1-derived macrophages
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Real-time quantitative PCR for characterizing gene
expression profiles
BAL cellular RNA was extracted, cDNA synthesized, and amplification
performed using custom oligonucleotide primers and probes (Microsynth,
Balgach, Switzerland; see details in the Methods and Table E1 in this article’s
Online Repository at www.jacionline.org).
Bacterial 16S ribosomal RNA gene amplification,
sequencing, and metagenome prediction
The 16S content of BAL fluidDNAwas characterized either by quantitative
PCR using previously reported primers specific to pan bacteria or by major
phyla (Bacteroidetes, Firmicutes, Proteobacteria, Actinobacteria, and
Fusobacteria), or Illumina MiSeq sequencing using primers targeting the
V1-V2 region, as previously described.11 Sequences were processed and
the resulting table of operational taxonomic units was used for
metagenome prediction, using Phylogenetic Investigation of Communities
by Reconstruction of Unobserved States (PICRUSt) software12 (see detail in
the Methods in this article’s Online Repository).
Bacterial cultures
Culture conditions for Staphylococcus aureus (ATCC 25904; ATCC,
Manassas, Va), Pseudomonas aeruginosa (ATCC BAA-47), Streptococcus
pneumoniae (NCTC 7466; Public Health England, Salisbury, UK), and
Prevotella melaninogenica (ATCC 25845) are provided in the Methods in
this article’s Online Repository. For stimulation experiments, suspensions
were diluted to reach a concentration of 4 3 1023 (P aeruginosa and
S pneumoniae) or 23 1023 (S aureus and P melaninogenica) optical density
at 600 nm corresponding to 106 colony-forming units (CFUs) per milliliter.
In vitro macrophage-fibroblast coculture model of
matrix deposition
Conditions for maintenance of human THP-1 monocytic cell line
(ATCC TIB-202) and MRC-5 fibroblasts (ATCC CCL-171), and macrophage
colony-stimulating factor 1-driven generation of THP-1-derivedmacrophages
(THP-DM) are provided in the Methods in this article’s Online Repository.
Stimulation using the bacterial suspensions described above, at a density of
5 CFUs per eukaryotic cell at day 0, was performed for 30 hours
(gene expression analysis) or 6 days (quantification of matrix deposition) in
minimum essential medium (Thermo Fisher Scientific, Rochester, NY),
supplemented with 70- and 400-kDa Ficoll (37.5 and 25 mg/mL, respectively;
GE Healthcare, Little Chalfont, UK) and transforming growth factor-b1
([TGF-b1], 5 ng/mL; eBioscience, San Diego, Calif) for optimal matrix
deposition, along with a mixture of prednisolone (500 nmol/L; Sigma,
St Louis, Mo)/FK506 (tacrolimus, 25 nmol/L; Enzo Life Sciences, Lausen,
Switzerland)/mycophenolic acid (10 mmol/L; Tocris Bioscience, Ellisville,
Mo). Penicillin and streptomycin (1000 U/mL and 100 mg/mL, respectively;
Thermo Fisher Scientific) were used to prevent bacterial growth, and cell
viability was assessed using a dedicated colorimetric assay (Cell Counting
Kit-8, Dojindo Molecular Technologies, Rockville, Md). Immunostaining
for collagen type 1 and fibronectin and automated image acquisition are
detailed in the Methods in this article’s Online Repository.
Principal component and statistical analysis
To analyze the distribution of BAL cell gene expression profiles, the target
gene/reference gene copy number ratio was log-transformed and principal
component analysis was performed using prcomp (scaled) routine in
R (R Foundation, Vienna, Austria).13 Multiple-group comparisons were
performed using Kruskal-Wallis test with Dunn post hoc analysis and
TABLE I. Patient characteristics
Patients/samples Total, no. 116/189
Male 58 (50.0)
Age at transplant (y) 52 (35, 61)
Sampling time point (days posttransplantation) 339 (92, 376)
Type of transplant Bilateral lung 101 (87.0)
Single lung 15 (12.9)
Pretransplantation diagnosis Chronic obstructive pulmonary disease 38 (32.8)
Cystic fibrosis 31 (26.7)
Interstitial lung disease 24 (20.7)
Graft failure (retransplantation) 5 (4.3)
Other 18 (15.5)
Transbronchial biopsies* 167 (88.4)
A0 128 (76.6)
A1 21 (12.6)
A2 5 (3.0)
B0 105 (62.9)
B1 19 (11.4)
B2 1 (0.6)
Immunosuppression* Tacrolimus 176 (93.1)
Cyclosporin 13 (6.9)
Antibiotics* TMP/SMX 143 (75.7)
Azithromycin 25 (13.2)
Other (inhaled, oral, or intravenous routes) 54 (28.6)
BAL positive bacterial culture
(excludes oropharyngeal flora)*
Staphylococcus aureus (n 5 10), Pseudomonas aeruginosa (n 5 10), S epidermidis (n 5 5),
Corynebacterium sp (n 5 4), Enterococcus sp (n 5 3), Streptococcus sp (n 5 1),
Klebsiella pneumoniae (n 5 1), Haemophilus influenzae (n 5 1), Escherichia coli (n 5 1),
Enterobacter sp (n 5 1)
32 (16.9)
BAL positive fungal culture* Aspergillus sp (n 5 4), Penicillium sp (n 5 3), Candida sp (n 5 4) 13 (6.9)
BAL positive viral PCR* CMV (n 5 11), EBV (n 5 2), metapneumovirus (n 5 1), parainfluenza (n 5 1) 14 (13.2)
Data presented as n (% of group) or median (IQR) unless otherwise indicated.
CMV, Cytomegalovirus; TMP/SMX, trimethoprim/sulfamethoxazole.
*At sampling.
Grading of pulmonary allograft rejection according to guidelines of the International Society for Heart and Lung Transplantation.9
Conducted in a subset (n 5 106) of samples. Virological investigations ranged from CMV only to more extensive testing, as per case requirement.
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posttransplantation differences in the relative abundance of the remodeling gene
expression profiles were compared using chi-square test (R package PMCMR).
In metagenomic prediction analysis, statistical significancewas evaluated using
DESeq2 package in R (P value < .05; log2 fold-change >2). Graphs were gener-
ated using Prism 6.0 software (GraphPad, La Jolla, Calif).
RESULTS
Experimental toolkit for determining remodeling
gene expression profiles in BAL cells
In a previous study, we showed that a majority of BAL samples
obtained from lung transplant recipients up to 14 months post-
transplantation can be distinguished on the basis of the expression
levels of a set of genes involved in inflammation and remodeling.7
However, a substantial group representing 43% of total samples
showed an intermediate profile and remained poorly character-
ized. Moreover, we noted an overlap across the whole sample
set in the expression of the selected remodeling markers—
platelet-derived growth factor D (PDGFD) and the tissue inhibitor
of metallopeptidase 1/matrix metallopeptidase 12 (MMP12)
ratio. These data highlighted the need to develop an analytical
toolkit able to further dissect the complexity of remodeling
gene expression profiles posttransplantation.
To this end, we employed 2 complementary approaches
(experimental scheme detailed in Fig 1, A). A subset of 9 BAL
samples, that represented an inflammatory, remodeling, or
intermediate gene expression profile in our first-round real-time
PCR, was analyzed by RNA sequencing. Data were filtered on
the basis of adjusted P value (.05 threshold) and ranked by
fold-change. In parallel, we selected 6 GO terms linked to
remodeling (see Fig 1, B for details) and interrogated the GO
database using the application AmiGO version 2.3,10 generating
a list of 627 candidate genes. Table II presents the restricted list
of 11 remodeling genes obtained after combining the 2
approaches, and further assessing potential candidates on the
basis of a literature survey on the remodeling-fibrosis axis, in
the context of various respiratory conditions. Real-time PCR
validation analysis indicated that expression of the selected genes
in our initial set of 9 BAL samples was associated with a
widespread distribution of corresponding eigenvectors, as ob-
tained by principal component analysis, consistent with
implications in diverse remodeling-related activities (Fig 1, C).
Indeed, the corresponding encoded proteins have been linked to
multiple aspects of remodeling, including matrix composition,
accumulation and degradation.14-21
Four host remodeling gene expression profiles
prevail in the transplanted lung
To gain further insight into remodeling gene expression profiles
posttransplantation, we analyzed by real-time PCR 189 BAL
samples obtained from 116 patients between 0.5 and 24 months
posttransplantation (see Table I for details)9 using our new
analytical toolkit. Principal component analysis (Fig 2, A) and
hierarchical clustering (Fig 2, B) allowed us to identify 4 profiles
that we defined as low, intermediate, anabolic, and catabolic
remodeling, representing 21%, 47%, 20%, and 12% of total
samples, respectively. Per-gene analysis confirmed that the low
and intermediate groups were indeed associated with low and
intermediate expression levels, respectively, of virtually all genes
First-round qPCR
203 BAL
112 patients, 0.5-14 mo
189 BAL
116 patients, 0.5-24 mo
Inflammation
Intermediate
Remodeling
Second-round qPCR
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conditions
9 representative
BAL for
screening analysis
 p-value adjustment
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FIG 1. Identification of a set of remodeling genes. A, Schematic outline of experimental approach. B, GO
criteria used in candidate gene selection process. C, Principal component (PC) analysis, and associated
eigenvectors, based on quantitative PCR determination of expression of the restricted list of 11 remodeling
genes (see Table II for details) in the initial subset of 9 BAL samples (dots).
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tested (Fig 2, C). Anabolic remodeling was characterized by
maximal expression of thrombospondin 1 (THBS1) and PDGFD,
2 factors previously linked to TGF-b-mediated repair in different
experimental and clinical settings (Fig 2, C).20,22 In contrast,
expression of several metallopeptidases (MMP7, MMP9, and
MMP12), typically associated with inflammation and matrix
degradation, distinguished the catabolic remodeling group. This
latter profile was also linked to a high expression of additional
remodeling markers, including the matrix constituents
collagen type VI a-2 and fibronectin 1, the growth-promoting in-
sulin-like growth factor 1 (IGF1), and the matricellular proteins
osteopontin (secreted phosphoprotein 1 [SPP1]), chitinase 3-
like 1 (CHI3L1), and IGF binding protein 2, all involved in the
regulation of matrix turnover (Fig 2, C). Spearman correlation
analysis confirmed these associations, with a coefficient (r)
ranging from -0.27 (PDGFD vs SPP1) to 0.78 (MMP9 vs
CHI3L1) indicating negative and positive correlation,
respectively (see Fig E1 in this article’s Online Repository at
www.jacionline.org).
We next observed that the different remodeling gene
expression profiles identified were linked to distinct kinetics
following transplantation (P < .05 by chi-square test) (Fig 2, D).
Specifically, low remodeling was almost limited to the first
12 months posttransplantation, while the intermediate profile
predominated in each of the 4 time windows considered (Fig 2,
D). We further observed that catabolic remodeling peaked
between 3 and 6 months, clearly preceding the maximal relative
frequency of anabolic remodeling, from 12 months onward
(Fig 2, D). This latter divergence in the kinetics of catabolic
versus anabolic remodeling was confirmed when we considered
87 combinations of paired samples obtained from 34 patients,
who were lavaged multiple times (median: 3, range: 2-6) (Fig 2,
E and Table E2 in this article’s Online Repository).
A schematic representation of these longitudinal transitions
between 2 different remodeling profiles further highlighted the
marked difference between the catabolic and anabolic profiles,
testified by a single direct transition (Fig 2, F). In contrast, the
intermediate remodeling profile was often connected to either
the low, anabolic, or catabolic remodeling profile, which is
consistent with a central position (Fig 2, F). Furthermore, we
observed a substantial degree of stability in remodeling gene
expression over time. Indeed, 34 paired samples (39%) were
linked to a stable profile, while 52 others (61%) showed a profile
transition. Moreover, when further focusing on 14 patients who
provided from 4 to 6 BAL samples (median: 4.5, interquartile
range [IQR]: 4, 5) over a range of 5.5 to 21 months (see
details in Table E2 in this article’s Online Repository at
www.jacionline.org), we found a median number of 2 profiles
(IQR: 2.0, 2.3). Here, the relative frequency of paired samples
with a stable profile decreased from the intermediate, anabolic,
catabolic, to low remodeling background (50%, 23%, 15%, and
12%, respectively). Overall, these observations support the
existence in the transplanted lung of distinct remodeling
activities, differentially interconnected, and regulated in a
time-dependent manner.
Relation between airway microbiota composition
and host remodeling gene profiling
We previously reported that the airway microbiota composi-
tion varies in concert with BAL cell gene profiling posttrans-
plantation.7 In particular, we showed that dysbiosis, defined by a
strong predominance of a single phylum exceeding 70% of rela-
tive abundance, was associated with a high expression of 2 con-
trasting sets of genes, linked to either inflammation or
remodeling, depending on the predominant phylum, while
more balanced bacterial communities aligned with a neutral
gene expression profile. We therefore investigated whether the
airway microbiota composition aligned with the 4 host remodel-
ing gene expression profiles identified in the present study, with
a special interest in the contrasting catabolic and anabolic pro-
files. For this purpose, we relied on a combination of molecular
analysis and culture, which proved complementary in distin-
guishing the composition of the airway microbiota associated
with a catabolic remodeling gene expression profile, versus
that linked to a low, intermediate, or anabolic profile. Specif-
ically, PCR amplification of the 16S ribosomal RNA (rRNA)
gene using phylum-specific primers indicated that dysbiosis
observed in 37% of total BAL samples was increased when
driven by Firmicutes or Actinobacteria, and decreased when
Bacteroidetes predominated, on a catabolic remodeling back-
ground (Fig 3, A). Moreover, sequence analysis at genus level
underscored the association of catabolic remodeling with Staph-
ylococcus, Corynebacterium, Stenotrophomonas, and Haemo-
philus (Fig 3, B). In contrast, a microbial community
comprising Prevotella, Streptococcus, Veillonella, and Neisse-
ria was poorly represented in this catabolic remodeling context,
while strongly predominating in association with low,
TABLE II. Remodeling gene set used for the characterization of BAL cell profiling*
Gene name, aliasy Gene symboly Molecular functions
Chitinase 3-like 1 CHI3L1 Regulator of cell-matrix interactions
Collagen type VI a-2 chain COL6A2 Matrix constituent
Fibronectin 1 FN1 Matrix constituent
Insulin-like growth factor 1 IGF1 Fibroblast proliferation and activation
Insulin-like growth factor binding protein 2 IGFBP2 Fibroblast proliferation and activation
Matrix metallopeptidase 7 MMP7 Mediator of matrix turnover; basement membrane proteolysis
Matrix metallopeptidase 9 MMP9 Mediator of matrix turnover; collagen and fibronectin proteolysis
Matrix metallopeptidase 12 MMP12 Mediator of matrix turnover; elastin proteolysis
Platelet-derived growth factor D PDGFD Fibroblast proliferation and survival
Secreted phosphoprotein 1, osteopontin SPP1 Regulator of cell-matrix interactions
Thrombospondin 1 THBS1 Regulator of cell-matrix interactions; major activator of TGF-b1
*Primer and probe sequences are available in Table E1 in this article’s Online Repository.
According to Human Gene Organization (HUGO) Gene Nomenclature Committee at the European Bioinformatics Institute.
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intermediate, or anabolic remodeling (Fig 3, B). These
specificities in the airway microbiota composition linked to
host catabolic remodeling gene expression profiling were also
accompanied by a reduced diversity compared with the 3 other
remodeling profiles (Fig 3, C).
Assessment of positive cultures confirmed Staphylococcus
spp and Corynebacterium spp, and additionally included
Pseudomonas spp, as part of the bacteria primarily linked to a
catabolic remodeling profile (Fig 3,D). In contrast, BAL samples
tested positive for oropharyngeal flora, which typically includes
bacteria of the genera Prevotella, Streptococcus, Veillonella,
and Neisseria,3 predominated in association with an anabolic
remodeling gene expression profile (Fig 3, D).
To explore further the links between the airway microbiota
composition and host gene expression, and given the early onset
of the catabolic remodeling profile, versus the late onset of the
anabolic remodeling profile, we next determined the relative
abundance of the different microbiota states within 4 time
windows posttransplantation (Fig 3, E). Here, we found that
microbiota dysbiosis was more likely to occur during the first
6 months posttransplantation when driven by Firmicutes, while
becoming more frequent over timewhen driven by Bacteroidetes,
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thus aligning with the kinetics of catabolic and anabolic
remodeling, respectively. Furthermore, we applied PICRUSt
analysis to gain insight on the predictive metagenome functions
of the bacterial communities linked to the 4 remodeling profiles.13
PICRUSt links operational taxonomic units, as identified by 16S
rRNA gene sequencing, to Kyoto Encyclopedia of Genes and
Genomes (KEGG) genes, their corresponding KEGG orthologs
(KOs) and, ultimately, functions. Global analysis of the predicted
metagenome indicated a segregation of the microbial
communities found on a catabolic remodeling background, which
especially differed from the communities associated with an
anabolic remodeling profile (Fig 3, F). To investigate potential
differences with respect to host remodeling more specifically,
we next considered a subset of 159 KOs related to bacteria-
matrix interaction and/or protein degradation. We found that 24
genes were significantly differentially represented (threshold set
to log2 fold-change >2) within the communities associated
with a catabolic, compared with an anabolic, remodeling profile
(Fig 3, G). Of note, 23 of those genetic markers, which included,
however not exclusively, virulence factors linked to infections of
various etiology, including S aureus and P aeruginosa, were
enriched (median log2 fold-change: 6.1, IQR: 2.3, 10.3; adjusted
P value <_ .01) in the communities associated with a catabolic
remodeling profile (Fig 3, G).
Host-microbe associations and the underlying
clinical situation
The relatively limited follow-up time in our study did not allow
us to look for associations between the observed features in host
remodeling gene expression or microbiota composition and the
onset of chronic rejection. Moreover, we found no link with the
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diagnosis of acute cellular rejection (A grade), as established on
histologic analysis of transbronchial biopsies (see Table E3 in the
Online Repository at www.jacionline.org). In addition, when
considering samples with a histologic diagnosis of airway
inflammation (lymphocytic bronchiolitis, B grade), we found
only a slight increase between the percentage of samples with a
catabolic remodeling signature versus those of samples with a
low, intermediate, or anabolic profile (21.4% vs 11.4%, 10.9%,
and 15.4%, respectively) (see Table E3 in the Online Repository).
However, confirming our previous findings,7 Firmicutes-,
Proteobacteria-, and Actinobacteria-driven dysbiosis, rather
than the absence of dysbiosis or Bacteroidetes-driven dysbiosis,
was found to be linked to histologically determined airway
inflammation (27.8%, 15.9%, and 4.8%, respectively) (see
Table E3 in the Online Repository).
To assess potential links among host remodeling, microbiota
states, and inflammation directly in the BAL, we next looked at
the cell differential and found a marked enrichment in
neutrophils, a hallmark of acute inflammation, accompanied by
a corresponding relative decrease in macrophage and lymphocyte
counts, on a catabolic remodeling background (Fig 4, A).
Consistently, we also observed a stronger expression of the
inflammation marker genes COX2 and TNF-a (Fig 4, B) in this
setting. These observations suggested that the microbial
communities linked to catabolic remodeling exhibit increased in-
flammatory properties in comparison to the principal members of
the community dominated by Prevotella,7,23 as previously
reported.
Given that the bacterial genera associated with catabolic
remodeling comprise common respiratory pathogens, we next
aimed to evaluate the links between host remodeling-microbe
associations and the diagnosis of infection. For this purpose, we
focused our attention on a subset of 29 BAL samples obtained
from patients who presented with clinical evidence of
infection and had a positive result in BAL culture by routine
microbiological examination and/or microbiota dysbiosis
detected by 16S rRNA gene amplification. BAL samples with
catabolic and anabolic remodeling gene expression profiles
aligned with maximal and minimal rates of clinical infection,
respectively (Fig 4, C). Moreover, when considering all of those
samples associated with a clinical suspicion of infection, we
found a striking difference in the bacteria identified by culture
and/or type of detected dysbiosis, depending on the remodeling
context (Fig 4, D). Hence, combined with the information we
obtained on the kinetics of gene expression profiles (Fig 2, D
and E) and microbiota states (Fig 3, E and F), this dataset
indicated that the early acquisition of a catabolic remodeling
profile and dysbiosis driven by highly stimulatory bacteria, is
linked to inflammation and a more frequent association with
clinical infection. In contrast, the clinical implications of the
coincident anabolic remodeling profile and dysbiosis driven by
low stimulatory bacteria, which are likely to be expressed later
following lung transplantation, remain to be defined.
The constituents of airway microbial communities
set the balance between anabolic and catabolic
remodeling
The identification of anabolic and catabolic gene expression
profiles linked to different airwaymicrobiota compositions raised
the possibility that the extracellular matrix turnover in the
transplanted lung is differentially influenced by the constituents
of local bacterial communities. To address this, we used an in vitro
model system that exploits the microbial sensing and
proremodeling capacities of THP-DM and MRC-5 fibroblasts to
compare the direct effects of bacterial mixes on remodeling
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gene expression profiles and matrix deposition. Culture
conditions were optimized for efficient matrix deposition, and
included immunosuppressive drugs, that mimicked the
transplanted lung environment and antibiotics, which effectively
prevented bacterial overgrowth (see the Methods for details).
This ensured consistent cell viability levels across the
different experimental conditions, in spite of a median 19%
decrease in the presence of S aureus and P aeruginosa versus
P melaninogenica and S pneumoniae (see Fig E2 in the Online
Repository). In this setting, bacteria identified in lung transplant
recipients on a catabolic remodeling background (a mix of
S aureus and P aeruginosa) induced a globally distinct
remodeling gene expression profile in macrophage-fibroblast
cocultures, as compared to the representatives of the
community linked to anabolic remodeling (P melaninogenica
and S pneumoniae) (Fig 5, A). Specifically, Staphylococcus and
Pseudomonas induced maximal expression of MMP7, -9, and
-12, while Prevotella and Streptococcus were linked to higher
THBS1 expression, 2 features aligning with catabolic and
anabolic gene expression profiling in BAL cells of lung transplant
recipients, respectively (Fig 5, B). Staphylococcus and
Pseudomonas were more potent in repressing expression of the
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marker of fibroblast to myofibroblast differentiation, a-smooth
muscle actin, along with that of the matrix components collagen
type 1 a1and fibronectin 1 (Fig 5, B). These divergent gene
expression profiles were ultimately reflected by a marked
decrease in matrix deposition linked to Staphylococcus and
Pseudomonas versus Prevotella and Streptococcus exposure, as
determined by collagen type 1 and fibronectin immunostaining
(Fig 5, C and D).
Consequently, this dataset underscored the critical role of
bacterial stimulation in the maintenance of homeostatic matrix
turnover, suggesting that the detrimental impact of airway
microbiota dysbiosis following transplantation may consist of
exaggerated anabolic or catabolic remodeling processes.
DISCUSSION
The view of the lower airways representing an ecosystem
implies that host cells and the constituents of the microbiota vary
in a coordinated manner, particularly in the case of a breakdown
in local homeostasis. Accordingly, different microbial
communities have been observed in association with lung
diseases such as asthma, chronic obstructive pulmonary disease
(COPD), and idiopathic pulmonary fibrosis, versus the healthy
state, with further changes prior, during, or following
exacerbations.4-6,23,24 The ecosystem associated with the
transplanted lung is shaped by the early and continuous
implementation of immunosuppression and the preventive or
therapeutic use of antibiotics. We have previously reported that
this lung habitat is linked to distinct microbial communities,
which can influence macrophage gene expression.7
The present study aimed to discriminate between anabolic and
catabolic remodeling following lung transplantation, given the
contrasting implications for graft fate these mechanisms may
have. In addition, we investigated the composition of lower
airway microbial communities on the different remodeling
backgrounds and addressed the impact of bacterial stimulation
on remodeling using an in vitro system of matrix deposition.
The 11 remodeling-related target genes we selected have all
previously been linked to respiratory conditions, though their
pathological role remains elusive.15,16,18,21,25-27 Functionally, the
corresponding encoded factors can be divided in 4 main cate-
gories: (1) matrix structural constituents (collagen type VI a-2,
fibronectin 1), which in myeloid cells are further known to modu-
late cell-matrix adhesion properties18,28; (2) matricellular pro-
teins (THBS1, SPP1, CHI3L1, IGF binding protein 2), which
comprise a variety of nonstructural, multifunctional factors, that
transiently bind to the matrix under specific conditions, notably
in association with lung injury, wound healing, and
fibrogenesis29; (3) matrix metallopeptidases (MMP7, -9, -12)
that fulfil multiple functions, but overall are associated with an
enhanced matrix degradation or turnover; (4) growth factors
(PDGFD, insulin-like growth factor 1), that regulate the
proliferation, migration, and survival of key remodeling cell
players.
Beside their implication in homeostatic matrix turnover, all of
these factors are involved in the control of lung injury, where they
function to ensure a time-dependent sequence of inflammatory
and remodeling processes, which ultimately lead to tissue repair.
Likewise, they have been linked to different respiratory
conditions, where their production varies with disease progres-
sion. Hence, both the physiological and pathophysiological
functions of these factors appear to be orchestrated in a
time-dependent manner. In this respect, our study, supported by
longitudinal data, shows marked differences in the kinetics of the
4 remodeling profiles identified following transplantation. Of
particular interest, the frequency of the catabolic remodeling
profile was maximal between 3 and 6 months, while the anabolic
remodeling profile peaked between 12 and 24 months
posttransplantation. Several factors associated with the catabolic
remodeling profile have been linked to inflammatory and/or acute
conditions, such as acute lung injury (SPP1),30 severe asthma
(CHI3L1),31 or COPD exacerbation (CHI3L1).25 Moreover, the
upregulated production of MMPs by inflammatory, epithelial,
and stromal cells, and the associated release in the lung and
circulation of matrix degradation products, have been observed
in a large panel of respiratory conditions, including CLAD versus
stable lung transplant recipients.32-35
In contrast, THBS1 and PDGFD, 2 factors linked to the
anabolic remodeling profile, have been reported to be part of a
positive feedback loop with the prototypical profibrogenic factor
TGF-b1, during tissue repair,20,36 promoting fibroblast
proliferation and myofibroblast differentiation.36,37 Collectively,
these observations suggest that the factors linked to the catabolic
and anabolic remodeling profiles identified are active in distinct
remodeling processes and/or stages.
The lower airway microbiota composition also varies over time
posttransplantation. We observed that a maximal frequency of
communities, strongly dominated by highly stimulatory bacteria
(from 3 to 6 months), coincided both with the peak of bacterial
infection and that of the catabolic remodeling profile. In marked
contrast, the maximal frequency of communities dominated by low
stimulatory bacteria (from 12 months onward), aligned with the
kinetics of the anabolic remodeling profile, suggesting that the
interplay among host cells, microbes, and the matrix represents a
key determinant of the lower airway microenvironment. In this
respect, data suggest that increases in BAL and/or circulating
matrix degradation products coincide with shifts in airway
microbiota composition during exacerbations in COPD and
idiopathic pulmonary fibrosis.5,6,34,38 Furthermore, matricellular
proteins play important roles in innate immunemechanisms linked
to both physiological bacterial colonization and infection, such as
the regulation of bioactive antibacterial peptide release.39,40
Our in vitro dataset indicates that S aureus and P aeruginosa,
typically associated with proinflammatory microbial
communities, trigger a stronger catabolic remodeling profile, in
comparison to P melaninogenica and S pneumoniae. This is
consistent with recent observations linking the 2 former bacterial
species to increased BAL levels of matrix glycosaminoglycans, as
compared to those associated with S pneumoniae, in acute
exacerbation and stable COPD, respectively.41 There are different
ways bacteria could modulate matrix production in our in vitro
system. Fig 5, A-D indicates that this occurred through
stimulation of fibroblasts and macrophages, by shifting the gene
expression balance between matrix components and
metalloproteinases. In addition, bacteria could have impacted
remodeling through direct degradation of the matrix. However,
given the presence of antibiotics in the culture medium, which
efficiently prevented bacterial metabolic activities, this second
mode of action is likely to be insignificant in this setting.
Consequently, we propose that the observed effects are linked
to the higher stimulatory potential of the microbe-associated mo-
lecular patterns, such as peptidoglycan and lipopolysaccharide,
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which contribute to the structural properties of bacterial cells in
Staphylococcus and Pseudomonas versus those in Prevotella
and Streptococcus. Regardless of the mechanisms involved, these
observations suggest that the net effect of host-microbe
interactions on matrix regulation closely depends on the
microbiota constituents. We propose that in the healthy state,
the lower airway microenvironmental conditions are linked to
low-grade matrix turnover and a balanced microbiota, which
contribute to local homeostasis. However, in respiratory diseases
associated with acute inflammation or fibrogenesis, local
conditions linked to a catabolic and anabolic remodeling profile,
respectively, promote the growth of specific bacteria, which in
turn differentially impact matrix regulation.
There were limitations to this study. First, although our in vitro
dataset revealed a link between remodeling gene expression
levels and activities, we acknowledge that remodeling in the
transplanted lung cannot be inferred solely from the identification
of BAL cell gene expression profiles, given the importance of
posttranscriptional regulation in this process. Nonetheless, the
different remodeling gene expression profiles we identified
correspond to distinct microenvironmental conditions, as
corroborated by specific features in the lung microbiota
composition and the underlying clinical state. Second, while the
anabolic and catabolic remodeling profiles distinguished 2
well-delineated sample groups, as further confirmed by their
association with contrasting bacterial communities, we found
no such associations for the low and intermediate remodeling
profiles. A possible underlying reason is that these 2 latter profiles
reflect local conditions that are convergent enough to
accommodate similar microbial communities. Alternatively, the
analytical tools we used to characterize gene expression profiling
and the composition of the airway microbiota might not have
reached the power required to further dissect existing
associations. Third, given that remodeling gene expression was
measured from unsorted BAL cells, we could not ascertain the
cellular source of gene transcripts, which would provide
information about the underlying pathophysiological processes.
Fourth, the posttransplantation follow-up period was not long
enough to enable us to assess any distinction between stable
transplant recipients and patients with CLAD. Given the
progressive nature and prevalence of this major obstacle to
long-term graft survival, further studies with a minimal 3-year
longitudinal follow-up are required to elucidate a link between
pulmonary bacterial dysbiosis, host gene expression profiling,
and eventually pathophysiological tissue remodeling. Fifth,
a direct assessment of the impact of antibiotics and
immunosuppressive drugs was precluded by the broad use, large
variability, and partly overlapping effects of the applied regimens,
within the context of lung transplantation. Sixth, a full picture of
the airway ecosystem should include an in-depth characterization
of the viral and fungal microbiota constituents. Notwithstanding
these shortcomings, our collective findings shed light on the
role of host-microbe interactions in the control of matrix turnover
after lung transplantation. Further increasing our understanding
of the mechanisms implicated may help decipher the
pathophysiology of CLAD and, by inference, that of other
respiratory conditions associated with lower airway remodeling.
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Key messages
d Four host remodeling gene expression profiles that align
with different bacterial communities prevail in the
transplanted lung.
d Typical bacterial pathogens that occasionally bloom
during the first months posttransplantation appear to
promote the degradation of the extracellular matrix,
while bacteria belonging to a healthy steady-state micro-
biota permit fibroblast to myofibroblast differentiation
and matrix deposition.
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METHODS
Patient sample collection
Patients underwent transoral or transnasal bronchoscopy. For BAL fluid
(BALF) collection, the bronchoscope was wedged either in the middle lobe or
lingula of the allograft and 100 to 150 mL of normal saline were instilled.
Different fractions of collected samples were submitted to cell differential
determination, culture-dependent bacterial and fungal detection, and
PCR-based detection of viral infection, according to routine clinical
procedures. Two fractions of 3 mL were stored at 48C and centrifuged within
3 hours at either 2,000g or 14,000g for 10 minutes, for future isolation of
BALF cellular RNA and total DNA, respectively. Pellets were snap frozen,
either after cell lysis in RLT buffer (Qiagen, Hilden, Germany) to preserve
RNA integrity, or directly, and were stored at2808C until further processing.
Samples obtained on washing the endoscope with sterile saline prior an
examination were prepared following the same procedure and were used as
negative control samples.
BALF cellular RNA extraction and real-time
quantitative PCR for gene expression analysis
BALF cell lysates were transferred into a QIAshredder column (Qiagen)
for homogenization and total RNA was extracted using RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions. RNA concentration
was determined using a Nanodrop ND-1000 spectrophotometer (Thermo
Fisher Scientific, Waltham, Mass) and reverse transcription was performed
using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, Calif).
Characterization of BALF cell remodeling profiles was based on multiplex
real-time PCR analysis of expression of a set of 11 genes (Table II). We used
guanine nucleotide-binding protein,b-polypeptide 2-like 1 gene as a reference
gene, given its high expression stability in BALF cells in both health and
disease.E1 Custom oligonucleotide primers and probes (Table E1) were
designed using National Center for Biotechnology Information (Bethesda,
Md) primer blast software and were purchased from Microsynth (Balgach,
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Switzerland). Amplificationwas carried out using iQMultiplex Powermix and
a CFX96 Real-Time detection system. Absolute quantification was performed
using the CFX Manager software 2.1 (all from Bio-Rad) based on values
obtained with a set of purified amplicons used as standards.
Bacterial metagenome prediction
The operational taxonomic units table obtained from 16S rRNA gene
sequencing data was normalized relative to the 16S rRNA gene copy number,
and the metagenomic content was predicted using PICRUSt software. The
predicted metagenome was exported as KOs for principal coordinate analysis
on Bray-Curtis distance, using the cmdscale function in R. To investigate the
potential functional capacity of the bacterial metagenome in respect to host
remodeling, a subset of 159 KOs related to matrix interactions (search terms
chondroitin*, collagen*, fibrinogen, fibronectin, hyaluron*) or protein/peptide
degradation (search terms protease, proteinase, peptidase, *lysin, *pain,
*staphin) were selected. All of these KOs were previously reported to be
linked to bacterial genomes.
Bacterial cultures
Staphylococcus aureus (ATCC 25904) and Paeruginosa (ATCC BAA-47)
were cultured on tryptic soy agar or in tryptic soy broth at 378C with 130 and
200 revolutions/min agitation, respectively (all media were obtained from
Becton-Dickinson, Franklin Lakes, NJ, unless otherwise specified).
Streptococcus pneumoniae (NCTC 7466) was grown on Mueller Hinton
agar with 5% sheep blood or in tryptic soy broth at 378C, in absence of
agitation in a 5% CO2 incubator. Prevotella melaninogenica (ATCC 25845)
was cultured on Columbia agar with 5% sheep blood or in chopped meat broth
(Remel Laboratories, Lenexa, Kan) at 378C under anaerobic conditions. For
stimulation experiments, bacteria were grown for 16 hours, washed twice in
PBS (BioConcept, Allschwil, Switzerland) at 3000g for 10 minutes at 48C,
and resuspended in X-VIVO 15 medium (Lonza, Basel, Switzerland).
Suspensions were finally diluted to reach a concentration of 4 3 1023
(Paeruginosa and S pneumoniae) or 23 1023 (S aureus and P melaninogen-
ica) optical density at 600 nm corresponding to 106 CFU/mL.
In vitro macrophage-fibroblast maintenance and
stimulation experiments
TheMRC-5 (ATCCCCL-171) human fibroblast cell linewasmaintained in
minimum essential medium with Earle’s salts, supplemented with
nonessential amino acids, sodium pyruvate, 10% (vol/vol) heat inactivated
FBS and 100 U/mL penicillin and 100 mg/mL streptomycin (all from Thermo
Fisher Scientific). The THP-1 (ATCC TIB-202) human monocytic cell line
was maintained in RPMI 1640medium supplemented with 10% (vol/vol) heat
inactivated FBS, 20 mmol/L 2-mercaptoethanol, 100 U/mL penicillin, and
100 mg/mL streptomycin (all from Thermo Fisher Scientific). Incubation was
at 378C in a humidified 5% CO2 atmosphere. For generating THP-DM,
24-well plates were precoated with FBS for 60 minutes. THP1 cells were
centrifuged at 300g for 10 minutes, resuspended in differentiation medium,
which corresponded to maintenance medium supplemented with human
recombinant Macrophage-Colony Stimulating Factor (Peprotech, Rocky
Hill, NJ), FBS (20% final concentration) and 10 mmol/L HEPES, and were
seeded into precoated 24-well plates at a density of 105 cells per well.
Incubation was for 7 days, without medium change. To assess gene expression
levels in macrophage-fibroblast cocultures in the presence or absence of
bacteria, fibroblasts and THP-DM were seeded at a density of 40,000 and
20,000 cells/cm2, respectively, in serum-free minimum essential medium
with Earle’s salts containing TGF-b1 (5 ng/mL; eBioscience, San Diego,
Calif), a mixture of prednisolone (500 nmol/L; Sigma, St. Louis,
Mo)/FK506 (tacrolimus, 25 nmol/L; Enzo Life Sciences, Lausen,
Switzerland)/mycophenolic acid (10 mmol/L; Tocris Bioscience, Ellisville,
Mo), and penicillin and streptomycin (1000 U/mL and 100 mg/mL,
respectively; Thermo Fisher Scientific). Bacterial suspensions were added
16 hours postseeding, at a total density of 3 3 105 CFU/cm2, which
corresponded to 5 CFU per eukaryotic cell at day 0, and the effects of
stimulation were assessed 30 hours later, when supernatants were removed
and cells were lyzed in RLT buffer (Qiagen) to preserve RNA integrity. Cell
viability was assessed 30 hours following the addition of bacterial mixtures
into macrophage-fibroblast cocultures, using a WST-1-based colorimetric
assay (Cell Counting Kit-8, Dojindo Molecular Technologies, Rockville,
Md), according to the manufacturer’s instructions.
In vitro assessment of matrix deposition
To optimize for maximal matrix deposition, macrophage-fibroblast
coculture medium was supplemented with 70- and 400-kDa Ficoll (37.5 and
25 mg/mL, respectively; GE Healthcare, Little Chalfont, UK).E2 Cocultures
were seeded at a density of 25,000 and 12,500 cells/cm2, respectively, in
m-Slide 8-well ibi-Treat slides (Ibidi, Martinsried, Germany), and were
incubated for 6 days without medium change, in the presence or absence of
bacteria, and thereafter supernatants were removed and cells were fixed in
4% paraformaldehyde in PBS for 20 minutes, for subsequent immunostaining
analysis.
Immunostaining, image acquisition, and
measurement of fluorescence area
Paraformaldehyde-fixed cells were permeabilized for 10 minutes in 0.2%
Triton X-100 in PBS, and further incubated for 30 minutes in 1% BSA
(Sigma-Aldrich, St Louis,Mo) in PBS to reduce nonspecific antibody binding.
Primary antibodies (mouse anti-human collagen type 1, Sigma-Aldrich; and
rabbit anti-human fibronectin, Abcam, Cambridge, UK) and secondary
antibodies (goat anti-mouse IgG Cy3, Merck, Darmstadt, Germany; and
goat anti-rabbit IgG AlexaFluor 488, Thermo Fisher Scientific) were
incubated for 2 hours and 1 hour, respectively, in 1% BSA in PBS. Incubation
with 49,6-diamidino-2-phenylindole dihydrochloride (10 mg/mL in methanol;
PanReac AppliChem, Darmstadt, Germany) was for 15 minutes. All steps
were performed at room temperature. For image acquisition, we used a
motorized inverted fluorescence microscope (Axio Observer Z1, Carl Zeiss,
Oberkochen, Germany) with 203 objective. A consistent predetermined
pattern of 8 images were acquired, both within and across experiments. The
process was automated using the Mark&Find function in AxioVision imaging
software (release 4.7.1, Carl Zeiss MicroImaging, Goettingen, Germany). The
fluorescence area was quantified and cell nuclei were counted with ImageJ
(version 1.50b) software (National Institutes of Health, Bethesda, Md).
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FIG E1. Spearman correlation coefficient matrix based on expression levels of the selected 11 remodeling
genes. Gene names are listed in Table II. Data are presented as Spearman r with P value, obtained by
analyzing by quantitative PCR expression of the 11 selected genes in the total set of 187 BAL samples.
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FIG E2. Cell viability determined in fibroblast-THP-DM cocultures, either in
the absence (no bacteria) or presence of bacterial mixtures, as indicated.
Data were pooled from 3 independent experiments with duplicates. Values
(mean6 SEM)were normalized to viability levels in the absence of bacteria.
Statistical significance was determined using Friedman test and Dunn post
hoc analysis.
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TABLE E1. Oligonucleotide primers and probes for analysis of BAL cell profiling
Oligonucleotide name NCBI gene ID NCBI reference sequence 59 label Sequence
CHI3L1_forward — 59-GATTTTCATGGAGCCTGGCG-39
CHI3L1_reverse 1116 NM_001276.2 — 59-CCCCACAGCATAGTCAGTGTT-39
CHI3L1_probe Tx Red 59-ACAGGCCATCACAGTCCCCTGTTCCGA-39
COL6A2_forward — 59-AGCTCTACCGCAACGACTAC-39
COL6A2_reverse 1292 NM_001849.3 — 59-CACCTTGTAGCACTCTCCGT-39
COL6A2_probe FAM 59-ACTCCACCGAGATCGACCAGGACACCA-39
MMP7_forward — 59-AAGTGGTCACCTACAGGATCG-39
MMP7_reverse 4316 NM_002423.4 — 59-TCAGCAGTTCCCCATACAACT-39
MMP7_probe Cy5 59-ACATGTGGGGCAAAGAGATCCCCCTGC-39
MMP9_forward — 59-GTACTCGACCTGTACCAGCG-39
MMP9_reverse 4318 NM_004994.2 — 59-AACAAACTGTATCCTTGGTCCG-39
MMP9_probe HEX 59-ACAGCGACAAGAAGTGGGGCTTCTGCC-39
IGF1_forward — 59-GCTTTTATTTCAACAAGCCCACAG-39
IGF1_reverse 3479 NM_001111283.2 — 59-GCCTCCTTAGATCACAGCTCC-39
IGF1_probe HEX 59-ACAGGCATCGTGGATGAGTGCTGCTTCC-39
IGFBP2_forward 59-AACCTCAAACAGTGCAAGATGTC-39
IGFBP2_reverse 3485 NM_000597.2 59-GTAGAAGAGATGACACTCGGGG-39
IGFBP2_probe Tx Red 59-AGCGTGGGGAGTGCTGGTGTGTGAA-39
SPP1_forward 59-TAAATTCTGGGAGGGCTTGGTT-39
SPP1_reverse 6696 NM_001040060.1 59-CATGGTAGTGAGTTTTCCTTGGTC-39
SPP1_ probe Cy5 59-AGGCCAGTTGCAGCCTTCTCAGCCA-39
THBS1_forward 59-GGAGGAGGGGTACAGAAACG-39
THBS1_reverse 7057 NM_003246.3 59-CAGGCATCCATCAATTGGACAG-39
THBS1_ probe FAM 59-ACCCCAGTTTGGAGGCAAGGACTGCGT-39
FN1_forward — 59-GGCTGGAGCCGGGCATTGAC-39
FN1_reverse 2335 NM_212482.1 — 59-GGGAGGAGGAACAGCCGTTTGTT-39
FN1_probe Tx Red 59-TGTAGTAGGGGCACTCTCGCCGCCA-39
MMP12_forward 59-TGCCCGTGGAGCTCATGGAGAC-39
MMP12_reverse 4321 NM_002426.4 59-CCTCCAATGCCAGATCCAGGTCCAA-39
MMP12_ probe HEX 59-AGCATGGGCTAGGATTCCACCTTTGCCATCA-39
PDGFD_forward 59-CCTCAGGCGAGATGAGAGCAATCAC-39
PDGFD_reverse 80310 NM_025208.4 59-TTCCTGGGGTAGCTGTTCGGGA-39
PDGFD_ probe Cy5 59-TGCACGTAGCCGTTTCCTTTCACCTGG-39
GNB2L1_forward — 59-CCAGCAGCAAGGCAGAACCACC-39
GNB2L1_reverse 10399 NM_006098.4 — 59-ACACTCGCACCAGGTTGTCCG-39
GNB2L1_probe Cy5.5 59-TGCACCTCCCTGGCCTGGTCTGCT-39
The primers and probes specific for CHI3L1, COL6A2, MMP7, MMP9; IGF1, IGFBP2, SPP1, THBS1; and FN1, MMP12, PDGFD were collectively used in multiplex-1, -2, and
-3, respectively. The primers and probe specific for GNB2L1, our reference gene,E1 were added into each multiplex.
Cy, Cyanine; FAM, fluorescein; GNB2L1, guanine nucleotide-binding protein, b-polypeptide 2-like 1; HEX, hexachloro-fluorescein; Tx Red, Texas Red.
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TABLE E2. Timing of BAL sample collection in patients with
multiple lavages
0.5-3* 3-6 6-12 12-24 Total samples
Pat. 1 1 1 2
Pat. 2 2 1 3
Pat. 3 2 2 2 6
Pat. 4 2 1 3
Pat. 5 2 2
Pat. 6 2 2 4
Pat. 7 2 1 3
Pat. 8 2 2 2 6
Pat. 9 2 2
Pat. 10 2 1 3
Pat. 11 2 2 4
Pat. 12 2 2
Pat. 13 1 2 1 4
Pat. 14 1 1 2
Pat. 15 1 1 2
Pat. 16 1 1 2
Pat. 17 2 1 1 4
Pat. 18 2 2 1 5
Pat. 19 1 1 2
Pat. 20 1 1 1 3
Pat. 21 2 2
Pat. 22 2 2 1 5
Pat. 23 2 1 1 4
Pat. 24 2 2
Pat. 25 2 2 1 5
Pat. 26 2 2 1 5
Pat. 27 1 2 1 4
Pat. 28 2 1 1 1 5
Pat. 29 2 2
Pat. 30 1 1 2
Pat. 31 1 1 2
Pat. 32 1 1 2
Pat. 33 1 1 2
Pat. 34 1 1 2
*Time window posttransplantation (months).
Patient code.
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TABLE E3. Sample distribution based on transbronchial biopsy evaluation*
Grade Low Anabolic Intermediate Catabolic
Firmi/Proteo/
Actino dysbiosis No dysbiosis Bact dysbiosis
Acute rejection A0 28 (80) 24 (80) 57 (86.4) 13 (81.3) 20 (87) 84 (81.5) 24 (92.3)
A1 (minimal) 5 (14.3) 6 (20) 7 (10.6) 3 (18.7) 3 (13.0) 16 (15.6) 1 (3.8)
A2 (mild) 2 (5.8) 0 (0) 2 (3) 0 (0) 0 (0) 3 (2.9) 1 (3.8)
Airway inflammation B0 31 (88.6) 22 (84.6) 57 (89.1) 11 (78.6) 13 (72.2) 69 (84.1) 20 (95.2)
B1-B2 (low grade) 4 (11.4) 4 (15.4) 7 (10.9) 3 (21.4) 5 (27.8) 13 (15.9) 1 (4.8)
Data presented as n (%) within each BAL cell gene expression profile or microbiota composition group.
Actino, Actinobacteria; Bact, Bacteroidetes; Firmi, Firmicutes; Proteo, Proteobacteria.
*Grading of pulmonary allograft rejection according to guidelines of the International Society for Heart and Lung Transplantation.E3
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